These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 16730854)

  • 1. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
    Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK
    Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.
    West HL; Wakelee HA; Perry MC; Belt RJ; Chen R; Obasaju C
    Ann Oncol; 2009 May; 20(5):850-6. PubMed ID: 19150937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
    Syrigos KN; Vansteenkiste J; Parikh P; von Pawel J; Manegold C; Martins RG; Simms L; Sugarman KP; Visseren-Grul C; Scagliotti GV
    Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV; Parikh P; von Pawel J; Biesma B; Vansteenkiste J; Manegold C; Serwatowski P; Gatzemeier U; Digumarti R; Zukin M; Lee JS; Mellemgaard A; Park K; Patil S; Rolski J; Goksel T; de Marinis F; Simms L; Sugarman KP; Gandara D
    J Clin Oncol; 2008 Jul; 26(21):3543-51. PubMed ID: 18506025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
    Heist RS; Wang X; Hodgson L; Otterson GA; Stinchcombe TE; Gandhi L; Villalona-Calero MA; Watson P; Vokes EE; Socinski MA;
    J Thorac Oncol; 2014 Feb; 9(2):214-21. PubMed ID: 24419419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
    Ma CX; Nair S; Thomas S; Mandrekar SJ; Nikcevich DA; Rowland KM; Fitch TR; Windschitl HE; Hillman SL; Schild SE; Jett JR; Obasaju C; Adjei AA; ; ;
    J Clin Oncol; 2005 Sep; 23(25):5929-37. PubMed ID: 16135464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer.
    Dudek AZ; Larson T; McCleod MJ; Schneider DJ; Dowell JE; Banerjee TK; Pandya KJ; Bromund JL; Chen R; Monberg MJ; Obasaju CK
    J Thorac Oncol; 2008 Apr; 3(4):394-9. PubMed ID: 18379358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
    Spigel DR; Hainsworth JD; Barton JH; Patton JF; Zubkus JD; Simons L; Griner P; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):841-5. PubMed ID: 20421819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
    Comella P; Chiuri VE; De Cataldis G; Filippelli G; Maiorino L; Vessia G; Cioffi R; Mancarella S; Putzu C; Greco E; Palmeri L; Costanzo R; Avallone A; Franco L
    Lung Cancer; 2010 Apr; 68(1):94-8. PubMed ID: 19545929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
    Gridelli C; Kaukel E; Gregorc V; Migliorino MR; Müller TR; Manegold C; Favaretto A; Martoni A; Caffo O; Schmittel A; Rossi A; Russo F; Peterson P; Muñoz M; Reck M
    J Thorac Oncol; 2007 Mar; 2(3):221-9. PubMed ID: 17410045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
    Yang CH; Simms L; Park K; Lee JS; Scagliotti G; Orlando M
    J Thorac Oncol; 2010 May; 5(5):688-95. PubMed ID: 20150825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
    Monnerat C; Le Chevalier T; Kelly K; Obasaju CK; Brahmer J; Novello S; Nakamura T; Liepa AM; Bozec L; Bunn PA; Ettinger DS
    Clin Cancer Res; 2004 Aug; 10(16):5439-46. PubMed ID: 15328182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
    Grønberg BH; Lund-Iversen M; Strøm EH; Brustugun OT; Scott H
    J Thorac Oncol; 2013 Oct; 8(10):1255-64. PubMed ID: 24457236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
    Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
    J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
    Spigel DR; Hainsworth JD; Shipley DL; Ervin TJ; Kohler PC; Lubiner ET; Peyton JD; Waterhouse DM; Burris HA; Greco FA
    J Thorac Oncol; 2012 Jan; 7(1):196-202. PubMed ID: 21900836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
    Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
    J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer.
    Blakely LJ; Schwartzberg L; Keaton M; Schnell F; Henry D; Epperson A; Walker MS
    Lung Cancer; 2009 Oct; 66(1):97-102. PubMed ID: 19167130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.
    Girard N; Jacoulet P; Gainet M; Elleuch R; Pernet D; Depierre A; Dalphin JC; Westeel V
    J Thorac Oncol; 2009 Dec; 4(12):1544-9. PubMed ID: 19884862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
    Scagliotti G; Brodowicz T; Shepherd FA; Zielinski C; Vansteenkiste J; Manegold C; Simms L; Fossella F; Sugarman K; Belani CP
    J Thorac Oncol; 2011 Jan; 6(1):64-70. PubMed ID: 21119545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.